Cardurion Pharmaceuticals is a next-generation cardiovascular biotech company founded by Dr. Michael E. Mendelsohn, a physician-Scientist with over 150 published articles. They focus on therapeutics that target cardiac myocyte signaling pathways to treat heart failure and other cardiovascular diseases. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.

Cardurion Pharmaceuticals

Executive Director, Biometrics

Associate Director, Biology, Cardurion Pharmaceuticals, K.K.

Centerbridge, Vistria seek minority stake sale of Sevita ahead of GP-led deal, Bain Capital invests in Cardurion Pharmaceuticals and Gluware - PE Hub

 Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing 

 Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company 

Ex-Merck executives launch Cardurion, with a kick-start ...

 Aminopyrimidine compound 

Chutes & Ladders—Cardurion taps Takeda veteran ...

The #OneCardurion team gathered in person and virtually to celebrate a great year and the upcoming holidays. Festivities included an Ugly Sweater Contest held during our virtual Town Hall, an onsite happy hour with cookie decorating, and hot chocolate sent out to all employees to enjoy. #HappyHolidays

It's National Nurses Week, and all at Cardurion are glad to recognize the critical role nurses play in patient care, our clinical trials and supporting positive health outcomes. #ThePowerOfNurses #NursesWeek #NursesWeek2025

Ex-Editas CEO Katrine Bosley chairs Arrakis board; Cardurion touts Polaris investment - Endpoints News

Cardurion Pharmaceuticals Appoints Marcia Moore as Chief Operating Officer - citybiz

Yesterday, #OneCardurion celebrated Culture Day (文化の日, Bunka no Hi), a national holiday in Japan dedicated to the promotion of culture, the arts, and academic endeavors. This day also considered a "sunny day" with a high probability of sunny weather.
#japanesecultureday

Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors

Cardurion Pharmaceuticals Bolsters Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer

As we close out the week, we are grateful to all of our employees traveling from near and far to spend time together. Here are a few more pictures of the week, including our happy hour and bowling night! #OneCardurion

Cardurion Pharmaceuticals Appoints Elizabeth Radcliffe as Chief Financial Officer - citybiz

 Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases 

Cardurion closes $260m in Series B to develop cardiovascular pipeline - Pharmaceutical Technology

Endpoints 11 winner Cardurion Pharmaceuticals: A shot at one of heart disease’s 'undruggable' targets - Endpoints News

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure

Today is Clinical Trials Day, and we are grateful for patients, their caregivers and trial site providers for their time and commitment to helping to advance medical research and improve health outcomes. We also recognize and appreciate the hard-working clinical trial professionals on our team at Cardurion. We are proud to be part of the Clinical Research community. Thank you! 

#ClinicalTrialsDay 

Today at the @Guggenheim Global Healthcare Conference, our CEO Peter Lawrence will participate in a panel discussion, entitled "Innovation Meets Experience: Uncovering Hidden Blockbuster Cardiovascular Opportunities." #GuggenheimPartners

We look forward to taking time over the holidays to rest and recharge. Wishing all #HappyHolidays!

Cardurion closes $260m in Series B to develop cardiovascular pipeline - Clinical Trials Arena

It’s #EmployeeAppreciationDay, and we’re grateful to have an amazing team of dedicated and passionate individuals at Cardurion. Thank you for your dedication to our company and our mission!

 Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 ... 

Cardurion Raises $260M to Advance Cardiovascular Assets - BioSpace

Interested in joining a fun team working at the forefront of cardiovascular innovation? Check out our job postings! #OneCardurion

https://lnkd.in/gDBjAzUh 

Cardurion raises another $260M to fuel heart drug pipeline - BioPharma Dive

Cardurion’s PDE9 inhibitor increases cGMP in Phase IIa heart failure trial - Clinical Trials Arena

 Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer 

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure - Yahoo Finance

 Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 ... 

 Cardurion Pharmaceuticals to Provide Update on CaMKII ... 

Bain invests $300M in Boston cardiovascular disease firm - The Business Journals

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

 Cardurion nabs Takeda plasma therapy R&D chief as new CMO 

 Ex-Editas CEO Katrine Bosley chairs Arrakis board; Cardurion touts Polaris investment 

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer - BioSpace

Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel

Cardiology Funding Roundup: Cardurion, Kestra, TRiCares all secure key investments - Cardiovascular Business

 Cardurion Pharmaceuticals Inks $260M Series B 

Takeda-backed cardiovascular biotech Cardurion nabs ...

 Cardurion Raises $260M to Advance Cardiovascular Assets 

At Cardurion, we're taking innovative approaches to develop  new treatments that have the potential to change the course of #cardiovasculardisease for patients. And we’re growing – join us!
#heartfailure #CVdruginnovation #OneCardurion

https://lnkd.in/gDBjAzUh 

Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Business Wire


                Silvia G. Priori to receive ACC Valentin Fuster Award for Innovation in Science
              

 Fused heteroaryl compounds and their use as camkii inhibitors 

Cardurion begins subject dosing in Phase II heart failure trial - Clinical Trials Arena

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Associ - PharmiWeb.com

 Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer 

Takeda Pharma partners with Cardurion Pharma - Express Pharma

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases - Yahoo Finance

 Meglumine salts of thienopyrimidines 

Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company - Business Wire

 Chutes & Ladders—Mylan's Coury steps into exec chairman role 

 Cardurion Pharmaceuticals Raises $260M Series B Financing 

Cardurion Pharmaceuticals synthesizes new CAMK2 inhibitors - BioWorld MedTech

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases - Business Wire

Lawrence lands Cardurion CEO job after helping ArQule to Merck buyout - Fierce Biotech

 Startup fund-raising in Mass. drops to 2020 levels 

Are you looking for a great team working together to make a difference for patients? Join us at Cardurion, where we're developing new medicines for #cardiovasculardisease and #heartfailure.

Learn more about opportunities here: https://lnkd.in/enC3_q4x 

Cardurion Pharmaceuticals Announces Investment of up to $300 Million from Bain Capital - Bain Capital

 Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer 

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Business Wire

We were glad to gather with so many others supporting heart health this past weekend as a sponsor of the American Heart Association Boston Heart and Stroke Ball. We enjoyed dinner, dancing and fundraising in support of lifesaving science, and improving health outcomes. #CVinnovation

During this season of gratitude in the U.S., we are thankful for our phenomenal team, both stateside and in Japan. We’re inspired by your dedication, spirit of collaboration and commitment to our mission to create new medicines for patients. #OneCardurion

Imara sells failed blood disorder drug to heart disease outfit Cardurion - Endpoints News

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure - Business Wire

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

Ex-Merck executives launch Cardurion, with a kick-start from Takeda - Fierce Biotech

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

Members of the Cardurion team gathered at our U.S. headquarters in Massachusetts for several days of collaboration. From team-building activities and a fabulous group dinner, to an expert guest speaker sharing perspectives on racial inequities in healthcare, to hearing from team members about the great science behind our programs, the gathering invigorated our work for #CVdruginnovation.

 Heart Failure Drugs Market Size Worth USD 21.63 Billion in 2032 | Emergen Research 

Happy new year! We enter the year grateful for our employees, investors, collaborators, clinical trial investigators and patients. We're excited to welcome 2025 and continue our work to improve the lives of people living with #heartfailure and #cardiovasculardisease.  
 
 #CVdruginnovation #OneCardurion

 Lawrence lands Cardurion CEO job after helping ArQule to Merck buyout 

 Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer 

Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure

Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

Cardurion Raises $260M to Advance Novel CV Drugs - Inside Precision Medicine

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023 - Business Wire

Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company

 Methods for treatment of heart failure 

Today kicks off Golden Week Golden Week, or Ōgon Shūkan (黄金週間), for our colleagues in Japan. We’re happy to join them in this celebration, which includes four national holidays within seven days, including Constitution Memorial Day on May 3 and  Children’s Day on May 5. #OneCardurion
 
Learn more: https://lnkd.in/enDuSfmF

Cardurion’s novel cardiovascular pipeline draws $260M series B - BioWorld Online

Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing - Genetic Engineering & Biotechnology News

 Cardio-focused Cardurion closes hearty $260M series B to challenge statin-dominated status quo 

Bain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets - Endpoints News

Cardio-focused Cardurion closes hearty $260M series B to challenge statin-dominated status quo - Fierce Biotech

 Cardurion Pharmaceuticals welcomes Ron Renaud to its Board of Directors 

After safety setbacks, job cuts, Imara sells its top drug to a startup - BioPharma Dive

The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises - Crunchbase News

 Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer 

Our legal team hosted a 90s-themed happy hour, and we had a great time reminiscing and relaxing together. #TeamTime

 Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure 

We’re delighted to welcome Karen Lewis as our new Chief People Officer. She brings more than 25 years of experience in human resources, helping build organizations and develop programs that support companies at various stages. We look forward to Karen’s insights and contributions as we position Cardurion for our next phase of growth and progress.
#CVdruginnovation #OneCardurion

Read more here: https://lnkd.in/e7UHivt4

Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company - BioSpace

 Cardurion Pharmaceuticals Welcomes Emma Reeve as ... 

Mintz Advises Cardurion Pharmaceuticals in Investment of up to $300 Million from Bain Capital - Mintz

As a company with accomplished women in STEM across every department, our management team and Board, we honor the achievements and contributions of all women, both at Cardurion and in our lives, on #InternationalWomensDay, March 8, and every day. We join the call to #AccelerateAction and continue progress towards an equitable world where difference is valued and celebrated. #IWD2025 #WomenInSTEM

Cardurion Pharmaceuticals

Drug notes:

About: